First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference
14 sept. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation
07 sept. 2022 07h00 HE
|
First Wave BioPharma, Inc.
Data suggest technology provides improved delayed-release profile that ensures adrulipase is delivered to targeted areas of the GI tract First Wave BioPharma expects to initiate Phase 2 trial...
First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract
31 août 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
29 août 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Reverse Stock Split
25 août 2022 12h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma, Inc. Announces Private Placement
15 juil. 2022 08h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Fecal Pancreatic Elastase Testing Market Is Set to Expand at A CAGR Of 7.7% To Reach US$ 30.2 Million By the Year 2032: FMI
20 avr. 2022 11h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
Companies Profiled in Fecal Pancreatic Elastase Testing Market are Laboratory Corporation of America® Holdings, DiaSorin, ScheBo Biotech AG, Immundiagnostik AG, Invivo Healthcare, DRG Instruments...
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
13 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new patient populations “Adrulipase Alfa” approved by...
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
18 août 2021 07h05 HE
|
AzurRx BioPharma, Inc.
MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
17 août 2021 07h00 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...